Tonix Pharma TNX-1500 data presented at American Transplant Congress

Tonix Pharmaceuticals Logo

Faculty at the Center for Transplantation Sciences, Massachusetts General Hospital, presented data at the 2022 American Transplant Congress about Tonix Pharmaceuticals’ (NASDAQ:TNXP) TNX-1500 product candidate in development for the prevention of organ transplant rejection. 

The presentations include data demonstrating that TNX-1500 showed activity in preventing organ rejection and was well tolerated in non-human primates.

The molecular target of TNX-1500 is CD40-ligand (CD40L), which is also known as CD154. Blockade of CD40L with TNX-1500 monotherapy consistently and safely prevented pathologic allo-immunity in a non-human primate cardiac allograft model without clinical thrombosis.

“To date, there has not been a humanized anti-CD40L antibody that can effectively prevent transplant rejections with acceptable level of tolerability,” Seth Lederman, M.D. and CEO of Tonix, said in a statement. 

TNX-1500 is a third generation anti-CD40L monoclonal antibody that has been designed by protein engineering to reduce the potential for thrombosis. 

“The animal studies found that TNX-1500 retains activity to prevent rejection and preserve graft function,” Dr. Lederman said. “We believe TNX-1500 has the potential for treating and preventing organ transplant rejection.”